|Brief Description||Principal Investigator|
|To investigate the safety and tolerability of selumetinib when given in combination with MEDI4736 to patients with advanced solid malignancies.||Kim, Edward Sanghyun|
|The primary objective of this NIS is to estimate the prevalence of positive PD-L1 status in a cohort of patients with recurrent/metastatic SCCHN who have reached second line treatment. PD-L1 status, as determined by biochemical evaluations on archival tumor samples, will be described for the overall study population with available tumor sample (taken in first line or second line setting) and in predefined sub-groups (e.g., HPV status, HIV status, smoking history, heavy alcohol use, anatomical su||Kim, Edward Sanghyun|
Primary: PFS, OS
Assess efficacy of MEDI4739 + tremelimumab combination compared to SoC in PFS, ORR, DoR, APR12, PFS2, OS, and OS24
Assess efficacy of MEDI4739 monotherapy compared to SoC in PFS, ORR, DoR, APR12, PFS2, OS, and OS24
|Carrizosa, Daniel Ricardo|
|In the neoadjuvant cohort, to investigate the safety and tolerability of neoadjuvant nivolumab administration in the following tumor types: HPV-positive (SCCHN), HPV-negative (SCCHN), Merkel Cell Carcinoma, Cervical, vaginal, or vulvar cancers. In the metastatic/recurrent cohort, to evaluate the investigator-assessed objective response rate (ORR) of nivolumab monotherapy and combination therapy of Nivolumab and Ipilimumab in subjects with the following diseases: Metastatic or recurrent nasophary||Amin, Asim|
I. To maintain a Childhood Cancer Registry for infants, children, adolescents, and young adults with cancer.
II. To utilize clinical and biological data to help determine eligibility or stratification, based on childhood cancer disease classification schemas, for potential enrollment of research subjects onto Children's Oncology Group (COG) therapeutic clinical trials.
III. To develop a well annotated childhood cancer biobank for current and future research through the collection of biospe
|Kaplan, Joel Adam|
|Overall survival: From randomization to date of death or last follow-up.||Moeller, Benjamin James|